{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Deleterious+BRCA1+Gene+Mutation",
    "query": {
      "condition": "Deleterious BRCA1 Gene Mutation"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T06:47:35.971Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02760849",
      "title": "Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Deleterious BARD1 Gene Mutation",
        "Deleterious BRCA1 Gene Mutation",
        "Deleterious BRCA2 Gene Mutation",
        "Deleterious BRIP1 Gene Mutation",
        "Deleterious EPCAM Gene Mutation",
        "Deleterious MLH1 Gene Mutation",
        "Deleterious MSH2 Gene Mutation",
        "Deleterious MSH6 Gene Mutation",
        "Deleterious PALB2 Gene Mutation",
        "Deleterious PMS2 Gene Mutation",
        "Deleterious RAD51C Gene Mutation",
        "Deleterious RAD51D Gene Mutation",
        "Hereditary Breast and Ovarian Cancer Syndrome",
        "Premenopausal"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Oophorectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Salpingectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Salpingo-Oophorectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 50 Years · Female only"
      },
      "enrollment_count": 374,
      "start_date": "2016-05-02",
      "completion_date": "2041-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-05-22T06:47:35.971Z",
      "location_count": 9,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 5 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02760849"
    },
    {
      "nct_id": "NCT03546972",
      "title": "Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Deleterious BRCA1 Gene Mutation",
        "Deleterious BRCA2 Gene Mutation",
        "Ductal Breast Carcinoma In Situ",
        "Obesity",
        "Overweight",
        "Premalignant Lesion"
      ],
      "interventions": [
        {
          "name": "Behavioral, Psychological or Informational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 70 Years · Female only"
      },
      "enrollment_count": 51,
      "start_date": "2017-12-17",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-05-22T06:47:35.971Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03546972"
    },
    {
      "nct_id": "NCT04171700",
      "title": "A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Rucaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "pharmaand GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2020-01-16",
      "completion_date": "2022-07-15",
      "has_results": true,
      "last_update_posted_date": "2023-10-02",
      "last_synced_at": "2026-05-22T06:47:35.971Z",
      "location_count": 19,
      "location_summary": "Los Angeles, California • San Francisco, California • Fort Myers, Florida + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04171700"
    },
    {
      "nct_id": "NCT03140670",
      "title": "Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "RUCAPARIB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2017-09-05",
      "completion_date": "2023-08-07",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-05-22T06:47:35.971Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03140670"
    },
    {
      "nct_id": "NCT03586661",
      "title": "Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Deleterious BRCA1 Gene Mutation",
        "Deleterious BRCA2 Gene Mutation",
        "Endometrial Adenocarcinoma",
        "High Grade Ovarian Serous Adenocarcinoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Progressive Disease",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Copanlisib",
          "type": "DRUG"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 31,
      "start_date": "2019-04-29",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-05-22T06:47:35.971Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03586661"
    },
    {
      "nct_id": "NCT04584255",
      "title": "Niraparib + Dostarlimab In BRCA Mutated Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage I Breast Cancer",
        "Stage II Breast Cancer",
        "Stage III Breast Cancer",
        "Breast Cancer",
        "HER2-negative Breast Cancer",
        "Germline BRCA1 Gene Mutation",
        "Germline BRCA2 Gene Mutation",
        "Deleterious PALB2 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Dostarlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2020-12-18",
      "completion_date": "2029-07-17",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T06:47:35.971Z",
      "location_count": 8,
      "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04584255"
    },
    {
      "nct_id": "NCT03845296",
      "title": "Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Deleterious BRCA1 Gene Mutation",
        "Deleterious BRCA2 Gene Mutation",
        "Loss of Heterozygosity",
        "Lung Non-Small Cell Squamous Carcinoma",
        "Recurrent Large Cell Lung Carcinoma",
        "Recurrent Lung Adenocarcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Recurrent Non-Squamous Non-Small Cell Lung Carcinoma",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Rucaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 64,
      "start_date": "2019-04-16",
      "completion_date": "2024-09-21",
      "has_results": true,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-05-22T06:47:35.971Z",
      "location_count": 950,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03845296"
    },
    {
      "nct_id": "NCT02326844",
      "title": "BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "BMN 673 (talazoparib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 99 Years · Female only"
      },
      "enrollment_count": 3,
      "start_date": "2015-03-02",
      "completion_date": "2016-04-14",
      "has_results": true,
      "last_update_posted_date": "2020-08-18",
      "last_synced_at": "2026-05-22T06:47:35.971Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02326844"
    },
    {
      "nct_id": "NCT02282345",
      "title": "Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Adenocarcinoma",
        "Deleterious BRCA1 Gene Mutation",
        "Deleterious BRCA2 Gene Mutation",
        "HER2/Neu Negative",
        "Invasive Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2015-04-16",
      "completion_date": "2022-06-07",
      "has_results": true,
      "last_update_posted_date": "2022-07-06",
      "last_synced_at": "2026-05-22T06:47:35.971Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02282345"
    }
  ]
}